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Background: Existing treatments are inadequate for patients at high risk of coronary heart disease caused by
elevated levels of plasma low-density lipoprotein cholesterol (LDL-C). Bambuterol is a prodrug of β2-agonist
commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD)with the advan-
tage of once daily dosing and favorable side effect proﬁle. The potential lipid-lowering effects of bambuterol were
unclear, possibly due to the racemic bambuterol (rac-bambuterol) that was used in previous studies.
Methods: The lipid-lowering effects of R-bambuterol were examined in a randomized phase I trial in 48 healthy
Chinese volunteers aged 18–45 years. Participants were randomly assigned to ﬁve groups to receive a single dose
(2.5 mg, 5 mg or 10 mg) or multiple doses (5 mg) of oral medications of R-bambuterol, or a single dose of rac-
bambuterol (10 mg). Plasma lipid levels were measured at baseline, time to peak concentration (Tmax) and
24 h after the treatment.
Findings: Administration of a single-dose of R-bambuterol resulted in dose-dependent reductions in the levels of
plasma LDL-C, high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), apolipoprotein B (ApoB) and
apolipoproteinA1 (ApoA1) at Tmax. Levels of LDL-C exhibited themost reductions,whichwere statistically signif-
icant in all three single-dose R-bambuterol groups (all P values b 0.05). R-bambuterol was more potent in LDL-C
lowering compared to rac-bambuterol at Tmax (P= 0.08). At 24 h after dosing, the signiﬁcant lipid lowering ef-
fects of R-bambuterol sustained for LDL-C (P=0.01), ApoB (P=0.001) and ApoA1 (P=0.03), but not for HDL-C.
The ratio of ApoA1/ApoB was marginally increased (P = 0.06). In the multiple-dose group, LDL-C levels again
were signiﬁcantly reduced (all P values b 0.05), whereas the ratios of ApoA1/ApoB were marginally increased.
Interpretation: R-bambuterol can lower the plasma levels of LDL-C, andmarginally raise the ratio of ApoA1/ApoB
(indicator of HDL-C/LDL-C) with both a single dose andmultiple doses. R-bambuterol was more potent in LDL-C
lowering than rac-bambuterol.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A high plasma concentration of low-density lipoprotein cholesterol
(LDL-C) is one of the major risk factors for coronary heart disease
(CHD) (Collaboration CTT, 2010; Reiner et al., 2011). Epidemiological
surveys have shown that LDL-C levels were log-linearly correlated
with CHD risk in a broad range of cholesterol levels (Grundy et al.,
2004). Clinical trials also demonstrated that effective reduction in LDL-
C can substantially reduce the risk of CHD (Collaboration CTT, 2010;
Anon., 1984; Canner et al., 1986). High potency statins have been used
to treat patients with hypercholesterolemia. However, taking statins
alone might not always achieve the optimal low level of LDL-CBioengineering, South China
, Panyu District, Guangzhou, PR
. This is an open access article under(Kuklina et al., 2009; Karalis et al., 2011). The effect of statins in primary
prevention of CHD, i.e. among thosewith elevated cholesterol levels but
without CHD, is also limited (Reiner, 2013). Moreover, 10–20% of the
patients taking statins experienced moderate to severe side effects, es-
pecially muscle damage (Zhang et al., 2013). It's also known that some
patients do not respond to statin treatment. Thus, additional options
for the treatment of hypercholesteremia are required.
Bambuterol is a prodrug of theβ2-agonist terbutaline. It is common-
ly prescribed for asthma and chronic obstructive pulmonary disease
(COPD) with once daily dosing and documented clinical safety (Olsson
and Svensson, 1984; D'Alonzo et al., 1995; Sitar et al., 1993). It has
been reported previously that bambuterol increases the level of high-
density lipoprotein cholesterol (HDL-C) in patientswith hyperlipidemia
(FlorÉN et al., 1997) and in patients with type II diabetes mellitus
(Bitzén et al., 1993) after six to eight weeks of treatments. However,
the cholesterol lowering effect of bambuterol, particularly on the level
of LDL-C, was only marginal and inconclusive (FlorÉN et al., 1997;
Bitzén et al., 1993). Bambuterol is a chiral drug with R- and S-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bambuterol in the previous studies might be related to the inefﬁcacy of
racemic bambuterol due to the different biological effects of enantio-
mers (Waldeck, 1993). Animal study clearly suggested a cholesterol
lowering effect of R-bambuterol in the treatment of tyloxapol-induced
hyperlipidemia in mice (Cheng and Tan, 2009). In addition, the previ-
ously inconclusive effects on plasma lipid of bambuterol were shown
in long term studies without a demonstration of a dose relationship.
In this study, using single optic pure enantiomers, we examined:
(1) dose–response effects of single dose R-bambuterol on plasma lipid
levels; (2) the differences of R-bambuterol versus Rac-bambuterol in
the effects of the lipid levels; and (3) effects of multiple doses R-
bambuterol on the lipid proﬁle in 48 healthy participants of a random-
ized phase I clinical trial.
2. Methods
2.1. Study Participants
All healthy individuals between the age of 18 and 45 and within the
normal range of body mass index (BMI, 19–24) were eligible to partici-
pate in the study. Before entering the study, all volunteers were
ascertained to be healthy by medical history, physical examination,
12-lead electrocardiography and routine laboratory tests. A total of 48
healthy Chinese volunteers were enrolled. None of the participants
used continuous medication such as lipid-lowering drugs or smoked.
None of the female participants were taking oral contraceptives or had
contraceptive implants. Written consent forms were obtained from all
study participants. The study was approved by the ethics committees
of 210 Dalian Army Hospital and followed the Good Clinical Practice
guidelines and the Declaration of Helsinki.
2.2. Study Design and Procedures
The study was as an open-label, randomized phase I study to assess
the pharmacokinetic and safety proﬁles of R-bambuterol. A sample sizeAssessed for e
Analysed  (n= 40 )
Allocated to R-bambuterol (n= 40 )
d 2.5 mg single dose(n= 10 )
d 5 mg single dose (n= 10)
d10 mg single dose (n= 10)
d5 mg multiple dose (n= 10)
Allocatio
Analys
Randomiz
Enrollment
Fig. 1. Studyof at least 8 healthy volunteers in each group is determined according to
the Chinese regulatory requirements, as stipulated by China State Food
and Drug Administration (SFDA). All study participants were randomly
randomized into ﬁve groups using a random number table and assigned
to receive single dose or multiple doses of oral medications of R-
bambuterol or rac-bambuterol (Key Pharma Ltd., China): (i) single dose
of R-bambuterol, 2.5 mg; (ii) single dose of R-bambuterol, 5 mg; (iii) sin-
gle dose of R-bambuterol, 10 mg; (iv) single dose of rac-bambuterol,
10 mg; (v) and multiple dose of R-bambuterol, 5 mg/day, for 7 days. All
medications were identically compressed in tablets.
All study participants stayed in the clinic of the 210 Dalian Army
Hospital during the clinical trial. Standard meals were served at desig-
nated times during the day. All subjects were fasted overnight for at
least 10 h and till 4 h after dosing. Each dose of R- or rac-bambuterol
was administrated with 200 mL water. All subjects were asked not to
drink more water until 2 h after dosing. For the single dose groups,
blood samples were collected at 1 h before dosing and at 0.25, 0.5, 1,
2, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 h after dosing. For the multiple
dose group, blood samples were collected at 1 h before dose 4 (day
4) and at 24 h after dose 4 to dose 7 (day 5 to day 8). In addition,
blood samples were collected at various time points, i.e. 0.25, 0.5, 1, 2,
3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 h, after dose 7. All laboratory analyses
were performed in the South China University of Technology in compli-
ance with Good Laboratory Practice (GLP) guidelines. The trial is regis-
tered with China SFDA, number 2010L01319.
2.3. Determination of Drug Concentration
Plasma extraction was performed using a validated method
developed in our laboratory. In brief, samples were precipitated by
acetonitrile, after which the supernatant was transferred into chro-
matography vials for UPLC/MS analysis. Albuterol was added into
each sample and served as internal standard. R or rac bambuterol
was separated on ACQUITY UPLC BEH HILIC column, 2.1 × 100 mm,
1.7 μm, (Waters Inc., MA, US) and analyzed with tandem quadrupole
(triple quadrupole) Mass spectrometry Xevo™ TQ-S (Waters Inc.,ligibility (n= 48 )
Excluded  (n= 0  )
Allocated to rac bambuterol (n= 8 )
d 10 mg single dose (n= 8 )
Analysed  (n= 8 )
n
is
ed (n= 48 )
proﬁle.
Table 1
Summary statistics of demographic and baseline characteristics.
R-bambuterol Racemic
bambuterol
Single dose Single dose
2.5 mg
(n = 10)
5.0 mg
(n = 10)
10 mg
(n = 10)
10 mg (n = 8)
Age (year) 25.1 ± 2.7 22.2 ± 2.5 22.2 ± 3.3 23.1 ± 2.1
Sex
Male 6 6 6 4
Female 4 4 4 4
BMI (kg/m2) 21.9 ± 1.6 21.0 ± 1.6 22.0 ± 1.6 21.7 ± 1.9
LDL-C (mmol/L) 2.2 ± 0.8 2.4 ± 0.9 2.3 ± 0.7 2.5 ± 0.8
HDL-C (mmol/L) 1.1 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 1.0 ± 0.2
TC (mmol/L) 3.7 ± 0.8 4.0 ± 0.8 4.1 ± 0.8 3.7 ± 0.8
TG (mmol/L) 1.2 ± 1.0 1.3 ± 0.9 1.8 ± 1.6 1.3 ± 0.9
ApoAI (mmol/L) 1.2 ± 0.1 1.2 ± 0.2 1.2 ± 0.2 1.1 ± 0.1
ApoB (mmol/L) 0.6 ± 0.1 0.7 ± 0.2 0.7 ± 0.1 0.7 ± 0.2
⁎ Abbreviations: BMB, bambuterol; BMI indicates body mass index; LDL-C, low density li-
poprotein cholesterol; HDL-C, high density lipoprotein; TC, total cholesterol; TG,
triglyceride.
Means ± standard deviation was shown for all continuous variables.
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ion pair (m/z 368.1/294.2).2.4. Lipid Analysis
LDL-C, total cholesterol (TC), HDL-C and TG were analyzed using
enzyme-based colorimetric assay (BioSino Bio-technology and Science
Inc., Beijing, China). ApoB and ApoA1 were measured using an
immunoturbidimetric assay (BioSino Bio-technology and Science Inc.,
Beijing, China). All assays were conducted following the manufactures'
instruction.2.5. Statistical Analysis
Percentage change in lipid parameter was calculated for each study
participant as the difference between the post-dose value and the base-
line value, divided by the baseline value. Lipid levelsmeasured at 1 h be-
fore dosing in the single dose groups and at 1 h before dose 3 in the
multiple dose groups served as baseline values. Mean percentage
changes and standard deviations (SD) were calculated for each treat-
ment group. Differences between treatment groups were assessed by
Student's t-test. Pearson correlation coefﬁcients were used to assess
the correlation between lipid parameters and plasma concentrations
of bambuterol. All statistical analyses were conducted using GraphPad
Prism version 6 (San Diego, CA). All P values were 2-sided. Values of P
less than 0.05 were considered statistically signiﬁcant.2.6. Role of the Funding Source
The sponsor supported part of the laboratory work.Table 2
Pharmacokinetics of R-bambuterol and rac-bambuterol.
Variables R-BMB
2.5 mg (n = 10) 5.0 mg (n = 10) 10
tmax (h) 1.5 (0.25–5) 1.5 (0.5–12)
Cmax (ng/L) 149.2 (110.3–201.8) 419.4 (251.6–699.0) 11
C24 (ng/L) BLQ 32.0 (17.3–39.4) 6
C24 Terbutaline (ng/L) 159.3 (110.3–230.1) 498.9 (362.1–687.3) 10
Tmax, time to reach peak concentration, expressed as median (range).
Cmax, maximum plasma concentration, expressed as the geometric means (95% conﬁdence int3. Results
3.1. Participant Characteristics
Forty-eight eligible healthy subjects were randomly assigned to re-
ceive 2.5 mg single-dose R-bambuterol (n = 10), 5 mg single-dose R-
bambuterol (n = 10), 10 mg single-dose R-bambuterol (n = 10),
5 mg multiple-dose R-bambuterol (n = 10), or 10 mg single dose rac-
bambuterol (n=8), respectively (Fig. 1). Baseline demographic charac-
teristics and lipid levels for the single-dose groupswere listed in Table 1.
There were no statistically signiﬁcant differences in age, BMI and base-
line cholesterol levels across different treatment groups. Total choles-
terol levels were normal (b5.2 mmol/L) in all except for two subjects
whose total cholesterol levels were borderline high (5.2-6.2 mmol/L):
one in the 2.5 mg single-dose R-bambuterol group and one in the
single-dose rac-bambuterol group. For subjects in the multiple-dose
group, blood collection started on the fourth day of treatment and
therefore the measurements before dose 4 (day 4) were used as base-
line. The levels of LDL-C,HDL-C, TC andTG all appeared to be lower com-
pared to those of the single-dose groups, although these groups were
not directly comparable (Suppl. Table 1).
3.2. Drug Responses and Pharmacokinetics of R-bambuterol
During the trial period, no serious adverse events were observed in
the participants who received R-bambuterol. No clinically signiﬁcant
dose-dependent changes were found in the tested laboratory indices,
i.e. liver function tests, kidney function tests, plasma electrolytes,
routine blood tests and urinalysis (data not shown).
The time to peak concentration (Tmax) and peak plasma concentra-
tion (Cmax) of bambuterol after administration of a single dose of R-
bambuterol or rac-bambuterol were shown in Table 2. In the 2.5 mg,
5 mg and 10 mg single-dose R-bambuterol groups, Cmax increased
with the dose (149.2 ng/L, 419.4 ng/L and 1136.0 ng/L, respectively)
and the corresponding Tmax were 1.5, 1.5 and 2 h, respectively. The
10 mg rac-bambuterol group had a more than two fold longer Tmax
and a 47% higher Cmax of bambuterol than the 10 mg R-bambuterol
group (Table 2). At 24 h after dosing, the plasma concentration of R-
bambuterol in the 10 mg group dropped to 68.7 ng/L whereas the con-
centration of its metabolite terbutaline was 1053.0 ng/L.
3.3. Lipid-lowering Effects of Single-dose R-bambuterol at Tmax
Administration of a single dose of R-bambuterol resulted in dose-
dependent reductions in the levels of plasma LDL-C, HDL-C, TC, ApoB,
andApoA1 at Tmax (Fig. 2). Levels of LDL-C exhibited themost reduction.
Percentage changes in LDL-C from the baseline measurements in the
2.5 mg, 5 mg, and 10 mg R-bambuterol groups were -2.9% (P= 0.05),
-6.7% (P= 0.05) and -12.4% (P= 0.01), respectively (Fig. 2A). Statisti-
cally signiﬁcant change in HDL-C level at Tmax was only observed in
the 10 mg R-bambuterol group (Fig. 2B, P = 0.05). The ratio of
ApoA1/ApoB, an indicator of the HDL-C/LDL-C ratio, increased with
dose, although the changes from baseline were not statistically signiﬁ-
cant (Fig. 1G). There is no obvious dose–response relationship for TGRac-BMB Multiple dose R-BMB (dose 7)
mg (n = 10) 10 mg (n = 8) 5 mg (n = 10)
2.0 (0.5–8) 4.5 (0.5–12) 2.0 (0.5–8)
36 (660.5–1952) 1668 (740.8–3756) 398.3 (166.2–954.7)
8.7 (38.2–123.4) 89.8 (42.7–188.8) 62.9 (32.2–122.8)
53 (748.6–1480) 702.2 (533.2–924.7) 783.0 (495.6–1237)
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Fig. 2. Lipid lowering effects of a single dose of R-bambuterol at Tmax. (A) LDL-C; (B) HDL-C; (C) TC; (D) TG; (E) ApoB; (F) ApoA1; (G) ApoA1/ApoB. Each subject received a single dose of R-bambuterol tablets of 2.5 mg, 5 mg or 10 mg orally. Values
shown are means of percentage changes. Error bars indicate standard deviation.
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360 Y. Ye et al. / EBioMedicine 2 (2015) 356–364(Fig. 2D). Correlations between Cmax of R-bambuterol and the corre-
sponding lipid levels at Tmax were examined in all study participants
who received a single dose of R-bambuterol (Suppl. Fig. 1). Again,
Cmax of R-bambuterol was signiﬁcantly correlated with a reduction in
LDL-C (R= -0.39, P=0.03) andmarginally correlated with an increase
in the ratio of ApoA1/ApoB (R= 0.33, P= 0.07).
3.4. Lipid-lowering Effects of R-bambuterol Versus Rac-bambuterol at Tmax
R-bambuterol appeared to bemore potent in lowering plasma lipids
than rac-bambuterol, particularly for LDL-C (Fig. 3, P= 0.08). At Tmax,
percentage reductions in LDL-C, TC, ApoB and ApoA1 in the 10 mg rac-
bambuterol group (6.6%, 5.0%, 7.6% and 5.9%, respectively) were similar
to the reductions in the 5 mg R-bambuterol group (6.7%, 4.0%, 7.8% and
5.5%, respectively), butwere approximately half of the reductions in the
10 mg R-bambuterol group (12.4%, 9.3%, 12.9% and 9.6%, respectively).
Reduction in HDL-C level in the 10 mg rac-bambuterol group, however,
was similar to that in the 10 mg R-BMB group at Tmax (Fig. 3, P=0.99).
3.5. Lipid-lowering Effects of Single-dose R-bambuterol at 24 h
The concentrations of R-bambuterol at 24 h after dosing were less
than one tenth of that at Tmax (Table 2). However, the lipid-lowing ef-
fects of R-bambuterol were still observed at 24 h after dosing (Fig. 4).
Percentage changes in LDL-C from the baseline measurements in the
2.5 mg, 5 mg, and 10 mg R-bambuterol groups were 1.2%,−1.3% and
−8.4%, respectively,with only the 10mggroup showed statistically sig-
niﬁcant reduction (P = 0.05). Levels of ApoA1 and ApoB were alsoLDL-C
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Fig. 3. Different lipid-lowering effects between R-BMB and rac-BMB. (A) LDL-C; (B) HDL-C; (C
2.5 mg, 5 mg or 10 mg, or a single dose of rac-bambuterol. Values shown are individual resultssigniﬁcantly reduced in the10mgR-bambuterol group at 24h after dos-
ing, whereas levels of HDL-C, TC, and TG were not. The ratio of ApoA1/
ApoB again showed a marginal increase at 24 h after dosing.
3.6. LDL Particle Size after Single-dose R-bambuterol Treatment
The LDL-C/ApoB ratio, an indicator of compositional changes in LDL
particle size, was calculated for all the single-dose R-bambuterol groups
(Fig. 5). Themean values of LDL-C/ApoBwere not signiﬁcantly different
between different treatment groups before dosing. No signiﬁcant
changes in LDL-C/ApoB ratios were noted at either Tmax or 24 h after
dose administration, which indicated minimal changes in LDL particle
sizes in each group.
3.7. Lipid-lowering Effects of Multiple-dose R-bambuterol at 24 h
The lipid-lowering effects of multiple doses of 5 mg R-bambuterol
were further studied. In the multiple-dose group, lipid proﬁles were
measured before dose 4 (day 4) and at 24 h after dose 4 to dose 7
(day 5 to day 8). The differences in lipid proﬁle between the measure-
ment before dose 4 (as baseline value) and the measurements at 24 h
after dose 4 to dose 7 were calculated and expressed as percentage
changes of the baseline value (Fig. 6). No signiﬁcant reductions in lipid
levels were observed at 24 h after dose 4 and dose 5 compared to the
lipid levels before dose 4. At 24 h after doses 6 and 7, signiﬁcant reduc-
tions in levels of LDL-C, TC and ApoBwere observed (all P values b 0.05).
The levels of HDL-C did not signiﬁcantly decrease at 24 h after doses 6
and 7, which led to marginal increases in ratios of ApoA1/ApoB (Fig. 6).L-C
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High plasma level of LDL-C is a major risk factor for coronary heart
disease. Conventional cholesterol-lowering treatments such as statin
are only modestly effective. Bambuterol is a type of β2-agonist com-
monly used for the treatment of asthma and COPD with the advantage
of once daily dosing and favorable side effect proﬁle (Olsson and
Svensson, 1984; D'Alonzo et al., 1995; Sitar et al., 1993). In this open-
label, randomized phase I clinical trial, we showed that R-bambuterol
signiﬁcantly lower the plasma levels of LDL-C, and marginally raise the
ratio of ApoA1/ApoB, an indicator of HDL-C/LDL-C, in less than 2 h
after administration and in a dose-dependent manner. We also showed
that R-bambuterol is more potent in cholesterol lowering than rac-
bambuterol. The lipid-lowing effects of R-bambuterol sustained after
24 h of treatment and after multiple doses. R-bambuterol therefore is
an attractive alternative or complement for other treatments to
decrease plasma LDL-C levels, and would be especially beneﬁcial for
those patients who also suffering from COPD.
The lipid-lowering effect of R-bambuterol was dose-dependent
(Fig. 2). A single dose of R-BMB signiﬁcantly lowered the levels of
LDL-C and marginally raised the ratio of ApoA1/ApoB at Tmax (less
than 2 h), therefore achieved a favorable lipid lowering effect in a
short term. Correlation between Cmax of R-bambuterol and the corre-
sponding lipid levels at Tmax further supported the lipid-lowering effect
of R-bambuterol (Suppl. Fig. 1).
The lipid-lowering effect of R-bambuterol was also observed at 24 h
after dosing, which appeared to be weaker. At 24 h, the concentration of
plasma R-bambuterol was less than one tenth of that at Tmax (Table 2).
It indicated that multiple mechanisms underlie the lipid-lowering effects
of R-bambuterol, namely the initial effects and the lagging effects. The ini-
tial effects were possibly related to the inhibition of butyrylcholinesterase
(Gazić et al., 2006). Butyrylcholinesterase activity has been associated
with cardiovascular risk factors, including the level of LDL-C (Stojanov
et al., 2011). The lagging effects were unlikely to be related to terbutaline
since the concentration of terbutaline at 24 h after treatment (Table 2)
was much lower compared to the previous study (Hooper et al., 1981).
In the multiple-dose 5 mg R-bambuterol group, the reduction in LDL-C
and the increase in ApoA1/ApoB at 24 h after dose 6 and dose 7 were
comparable to those in the single-dose group. These results suggested po-
tential long-term cholesterol-lowering effects of R-bambuterol.
The lipid-lowering effects of R-bambuterol and rac-bambuterol
were compared. At Tmax, percentage changes in LDL-C, TC, ApoB and
ApoA1 in the 10 mg rac-bambuterol group were similar to those in
the 5 mg R-bambuterol group, but only approximately half of those in
the 10 mg R-bambuterol group (Fig. 3), suggesting that R-bambuterol
was more potent. R-bambuterol made up half of rac-bambuterol. It is
possible that R-enantiomer of bambuterol is the eutomer which
accounted for most of the observed cholesterol-lowering effects of
rac-bambuterol. Similar ﬁndings in previous study in guinea pigs
showed that the protective effect of R-bambuterol from histamine in-
duced bronchoconstriction is stronger than that of rac-bambuterol
(Cheng and Tan, 2009).
Previously, adverse effects, i.e. fatigue, nausea, palpitations, head-
ache, dizziness and tremor have been reported for rac-bambuterol
(Holstein-Rathlou et al., 1986). It has been suggested R-bambuterol
has less cardiac inotropic and chronotropic effects than rac-BMB in
animals (Cheng and Tan, 2009). In this study, R-bambuterol adminis-
tered either as single (10 mg) or as multiple doses (5 mg/daily) was
well tolerated since the lower dose used compared to previous studies
(10 mg/daily versus 20 mg daily). Several studies suggested associa-
tions between the regular use of β2-agonist and non-fatal ischemic
heart disease (Martin et al., 1998) or asthma death (Cazzola and
Matera, 2007). Based on our ﬁndings, these adverse effects may be re-
duced by using R-bambuterol enantiomer which requires only one
half of the dose of rac-bambuterol while limiting the possible non-
target effects of S-bambuterol.FlorÉN et al. (1997) reported that rac-bambuterol treatment signiﬁ-
cantly increases the level of HDL-C, but not signiﬁcantly change the level
of LDL-C. The effect was different from our ﬁndings, possibly due to the
different experimental settings and the rac-bambuterol administrated.
In the previous study, the treatment period was 6–8 weeks, whereas
in this study the dosing period of R-bambuterol was only one to seven
days. Also, the previous study was conducted among patients with hy-
perlipidemia, who were also at older age (mean age of 59.3 years).
More importantly, R-bambuterol and S-bambuterol might have differ-
ent or even contradicting biological effects, which have been observed
for other racemic drugs (Caner et al., 2004). Nevertheless, the approxi-
mately 15% LDL-C lowering and the marginal ApoA1/ApoB increasing
effects of R-bambuterol within a short-term treatment observed in
this study is noteworthy.
Limitations of the study include the small study population, the lack
of control group, and the short term of treatment. More studies with
longer periods of treatment and among larger populations are required
to deﬁne the more accurate effects of R-bambuterol on lipid levels in
healthy population. In addition, a phase II trial with high cholesterol
patients will be needed for better understanding of the lipid lowering
effects by R-bambuterol.
The lipid-lowering effect of R-bambuterol was likely different from
that of ﬁbrates and niacin, which also effectively reduced plasma TG
levels (Bruckert et al., 2011; Fabbrini et al., 2010). A higher LDL-C/
ApoB ratio indicates an increase in the LDL particle size. Unlike statins
and ﬁbrates (Watts et al., 2006; Ballantyne et al., 2008), the administra-
tion of R-bambuterol did not signiﬁcantly alter the LDL-C/ApoB ratio
(Fig. 4). In addition, oral administration of R-bambuterol in this study
did not signiﬁcantly alter the plasma concentration of glucose or potas-
sium (data not shown), which were found in previous clinic studies
when orally administering Rac-bambuterol and other racemic β2-ago-
nists such as albuterol.
In conclusion, this study showed that R-bambuterol can lower the
plasma levels of LDL-C, and raise the ratio of ApoA1/ApoB (indicator of
HDL-C/LDL-C) when administered in either a single dose or multiple
doses. R-bambuterol was more potent in lipid-lowering than rac-
bambuterol. Therefore, R-bambuterol might offer an alternative treat-
ment for patients with high LDL-cholesterol level, especially for whom
also suffering from COPD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.02.006.
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